Abstract Number: 0346 • ACR Convergence 2023
Use, Safety and Persistence of Biosimilars in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events of Targeted Therapies in Rheumatic Diseases (BIOBADASER)
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood. The emergence of new biologic agents has led to changes in…Abstract Number: 0370 • ACR Convergence 2023
Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in children with juvenile spondyloarthritis (JSpA) and generally represent the first-line choice for biologic therapy. However, not…Abstract Number: 0833 • ACR Convergence 2023
Machine Learning Detected Healthcare Encounter Patterns Leading to Diagnosis of Juvenile Arthritis in a Population-Based Canadian Cohort
Background/Purpose: Increases in health care visits precede the first diagnosis code for inflammatory arthritis (IA) by an average of 5 years in adults, but it…Abstract Number: 1230 • ACR Convergence 2023
Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by multiorgan vasculopathy, and degree of vasculopathy can indicate more severe disease. Nailfold capillaroscopy is a non-invasive method to…Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…Abstract Number: 1661 • ACR Convergence 2023
Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin
Background/Purpose: Recent single-cell RNA sequencing (scRNA seq) data has been generated across several tissues in autoimmune diseases, helping to understand the cellular and molecular underpinnings…Abstract Number: 2049 • ACR Convergence 2023
Vaccination Coverage and Caregiver Perspectives for Children with Rheumatic Diseases Compared to Healthy Controls
Background/Purpose: Children with rheumatic diseases (RD) have an increased incidence of infections and their complications, both from underlying disease activity and immunosuppressive treatments. Vaccines have…Abstract Number: 2475 • ACR Convergence 2023
Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis of young children that can lead to the development of coronary artery aneurysms (CAA) in up to…Abstract Number: 0349 • ACR Convergence 2023
Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) are a group of heterogeneous arthritis with onset in childhood. According to previous studies, this patients experience an improvement of…Abstract Number: 0371 • ACR Convergence 2023
Assessing Methotrexate Adherence in JIA Using Electronic Health Record-Linked Pharmacy Dispensing Data
Background/Purpose: The extent to which lack of adherence to prescribed treatment regimens contributes to differential disease outcomes in JIA – and demographic disparities in these…Abstract Number: 0834 • ACR Convergence 2023
Characterization of the Youngest Cohort with Non-Systemic Juvenile Idiopathic Arthritis: Demographics and Medication Use of Patients ≤2 Years of Age in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Tumor necrosis factor inhibitors (TNFi) have demonstrated efficacy and safety in older…Abstract Number: 1231 • ACR Convergence 2023
Successful Implementation of a Mental Health Screening Program for Youth with Juvenile Dermatomyositis
Background/Purpose: High levels of emotional distress have been reported in children with juvenile myositis (JM). Inadequate recognition of mental health concerns by healthcare providers (HCPs)…Abstract Number: 1251 • ACR Convergence 2023
Neurologic Manifestations of Pediatric Sjogren’s Disease Patients: Case Series from an Academic Children’s Hospital
Background/Purpose: The prevalence of Sjogren's disease (SD) is becoming increasingly recognized in pediatric rheumatology. Despite fewer sicca symptoms, it has been shown that pediatric SD…Abstract Number: 1686 • ACR Convergence 2023
Adolescent and Young Adult Rheumatology Patient Reports of Reproductive Health Screening and Counseling in the Clinical Setting
Background/Purpose: Adolescents and young adults (AYAs) with rheumatic disease are at high risk of poor reproductive health outcomes due to disease-related risks and teratogen use.…Abstract Number: 2050 • ACR Convergence 2023
Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey
Background/Purpose: Immunocompromised children (ICC), including children with rheumatic diseases receiving immunosuppressive therapies (IST) are at increased risk of morbidity from vaccine-preventable infections. The 2022 American…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 52
- Next Page »